Medical Management of Chronic Lung Disease of Prematurity (Bronchopulmonary Dysplasia)
For infants with established BPD, optimize respiratory support to maintain adequate oxygenation while minimizing ventilator-induced injury, provide targeted nutritional support, and reserve systemic corticosteroids for ventilator-dependent infants at high risk (>50-70%) of severe BPD, using medium-dose dexamethasone (2-4 mg/kg cumulative) initiated between days 8-14 of life.
Core Management Strategy
The management of BPD requires an algorithmic approach based on disease severity and timing:
Respiratory Support
- Primary goal: Maintain adequate gas exchange (SpO2 90-95%) while promoting lung growth 1
- Minimize ventilator-induced injury through gentle ventilation strategies
- Progress from invasive to non-invasive support (nasal CPAP, high-flow nasal cannula) as tolerated
- For severe BPD requiring prolonged support, consider tracheostomy if ventilator dependence extends beyond several months 2
Pharmacological Management
Corticosteroids - The Critical Decision Point
Systemic dexamethasone is the most evidence-based pharmacological intervention, but timing and dosing are crucial:
- Use medium-dose dexamethasone (2-4 mg/kg cumulative dose) initiated between days 8-14 in ventilator-dependent infants with >50-70% risk of developing BPD 3
- This regimen reduces BPD/death and may improve survival without neurodevelopmental impairment
- Avoid high-dose dexamethasone (>0.5 mg/kg/day) - provides no additional benefit and increases adverse outcomes 4
- Do NOT use dexamethasone in infants with <30% BPD risk - meta-regression shows harm exceeds benefit in this population 3
- Low-dose dexamethasone, hydrocortisone, and inhaled corticosteroids are ineffective for BPD prevention 3
Critical caveat: The 2010 AAP guideline 4 recommended limiting dexamethasone use to exceptional circumstances, but newer evidence from 2026 3 demonstrates that medium-dose dexamethasone initiated moderately early (days 8-14) in appropriately selected high-risk infants reduces BPD without increasing neurodevelopmental impairment. This represents an evolution in the evidence base.
Bronchodilators
For infants and children with established BPD and respiratory symptoms:
- Trial short-acting bronchodilators (albuterol/salbutamol) ONLY in patients with recurrent respiratory symptoms (wheeze, cough, dyspnea) 5
- Do NOT routinely prescribe bronchodilators to asymptomatic patients with BPD 5
- Monitor clinical response - approximately 35-75% of BPD patients respond to bronchodilators, with higher response rates in those with wheezing 5
- Response is more likely in patients with atopy, family history of asthma, or recurrent wheeze 5
Important distinction: Children with BPD may have fixed airway obstruction or tracheomalacia rather than reversible bronchospasm, making them less responsive than typical asthmatics 5
Inhaled Corticosteroids
- Evidence is insufficient to recommend routine use in BPD patients 5, 6
- Consider a trial in patients with recurrent wheezing who demonstrate bronchodilator responsiveness
- These patients may have overlapping asthma phenotype
Diuretics
- Provide only short-term improvements in lung function with significant side effects 6
- Reserve for acute exacerbations or severe fluid overload
- Not recommended for routine chronic use
Pulmonary Hypertension Management
For infants with BPD-associated pulmonary hypertension (a major complication in severe BPD):
- First-line: Sildenafil to improve oxygenation 2
- Second-line: Bosentan if inadequate response to sildenafil 2
- Screen for pulmonary hypertension with echocardiography in moderate-severe BPD
Nutritional Optimization
- Aggressive nutritional support is essential - growth failure is common and worsens outcomes 7
- Increase caloric density to support catch-up growth while managing fluid restrictions
- Vitamin A supplementation has preventive benefits 8
Caffeine
- Continue caffeine therapy - proven effective for BPD prevention 8
- Maintain through at least 34-36 weeks postmenstrual age
Common Pitfalls to Avoid
Using late, low-dose dexamethasone (after 3-4 weeks at <2 mg/kg) - this is currently prevalent but less effective than moderately early, medium-dose regimens 3
Prescribing bronchodilators to all BPD patients - only those with recurrent symptoms benefit 5
Assuming all wheezing in ex-preterm infants is asthma - many have fixed obstruction or structural airway disease that won't respond to typical asthma therapy 5
Aggressive treatment of patent ductus arteriosus - evidence suggests "wait and see" is preferable 6
Post-Discharge Management
Infants with moderate-severe BPD require:
- Multidisciplinary follow-up including pulmonology, nutrition, developmental specialists 7
- Monitoring for respiratory infections (high rehospitalization risk in first 2 years) 9
- Assessment for pulmonary hypertension, systemic hypertension 7
- Neurodevelopmental surveillance - BPD is a top risk factor for impairment 3
- Home oxygen if needed to maintain SpO2 >90% 2
- Long-term respiratory follow-up into adolescence and adulthood given risk of early-onset COPD 10, 9
The evidence base continues to evolve, with the most recent high-quality data 3 supporting more aggressive use of appropriately-dosed systemic corticosteroids in carefully selected high-risk infants, representing a shift from the more restrictive 2010 recommendations 4.